Vir Biotechnology (VIR) announced the enrollment of the first patient in its Phase 3 ECLIPSE registrational program. The ECLIPSE registrational program is designed to evaluate the efficacy and safety of tobevibart in combination with elebsiran in people living with chronic hepatitis delta.
Easter Sale - 70% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VIR:
- Vir Biotechnology’s Strategic Advancements and Financial Health Justify Buy Rating
- Vir Biotechnology Poised for Growth: Buy Rating Reiterated Amid Clinical and Financial Advancements
- Vir Biotechnology price target raised to $31 from $26 at Barclays
- Vir Biotechnology’s Transformative Year: Earnings Call Insights
- Promising Oncology Developments and Strong Financial Outlook Support Buy Rating for Vir Biotechnology